Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 14,763 shares of Class A common stock on February 23, 2026, at weighted average prices between roughly $38.40 and $40.46 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. After these transactions, Budge directly owned 420,132 shares of Hinge Health Class A common stock.
James Pursley reported a planned sale of 15,000 common shares of HNGE under a 10b5-1 arrangement. The filing shows the sale date 12/22/2025 and a gross sale amount of $725,950.50. The shares trace to Performance Stock Units dated 04/01/2023.
James Budge reported a proposed sale of 14,763 restricted stock units of HNGE via Form 144. The filing lists prior 10b5-1 sales of Common stock: 10,491 shares on 12/22/2025 for $507,836.79 and 44,589 shares on 11/25/2025 for $2,116,778.06. The securities to be sold are described as Restricted Stock Units with an effective date of 01/01/2026.
Hinge Health, Inc. director and 10% owner Robinson Elliott filed a Form 4 reporting open-market sales of Class A Common Stock by affiliated Bessemer funds. On February 17, 2026, Bessemer Venture Partners X L.P. sold 46,276 shares and Bessemer Venture Partners X Institutional L.P. sold 43,440 shares at a weighted average price of $39.929. On February 18, 2026, BVP X sold 48,353 shares and BVP X Inst sold 45,390 shares at a weighted average price of $40.358. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these holdings and disclaims beneficial ownership beyond any pecuniary interest.
Hinge Health, Inc. director, CEO and co-founder Daniel Antonio Perez reported indirect changes in ownership of Class A and Class B common stock held by his spouse. On February 17, 2026, 7,260 shares of Class B Common Stock were converted into 7,260 shares of Class A Common Stock at a price of $0.00 per share. The same day, 7,260 shares of Class A Common Stock held indirectly through his spouse were transferred as a bona fide gift, also at $0.00 per share. Following these transactions, spouse-held Class A Common Stock stood at 35,470 shares and spouse-held Class B Common Stock at 508,445 shares, while 9,488,845 shares of Class B Common Stock were reported as directly held.
Hinge Health, Inc. received an amended Schedule 13G showing that investment firm Coatue Management, its related funds, and Philippe Laffont now report 0 shares of Class A common stock beneficially owned.
Each reporting person states 0% of the class as of 12/31/2025, confirming ownership of five percent or less of Hinge Health’s outstanding Class A shares.
Hinge Health, Inc. received an updated ownership report from Bessemer Venture Partners and affiliated Deer X entities regarding their holdings of the company’s Class A common stock, as of a reference date tied to October 30, 2025 share counts.
Deer X Ltd and Deer X LP each report beneficial ownership of 3,133,707 shares, representing 8.3% of the Class A common stock. Bessemer Venture Partners X L.P. reports 1,616,366 shares, or 4.3%, and Bessemer Venture Partners X Institutional L.P. reports 1,517,341 shares, or 4.0%. These positions reflect Class A shares underlying Class B common stock that is convertible into Class A on a 1-for-1 basis, based on 37,919,155 Class A shares outstanding as of October 30, 2025.
Hinge Health director and 10% owner Robinson Elliott, through Bessemer venture funds, reported indirect sales of the company’s Class A common stock. On February 12, 2026, Bessemer Venture Partners X L.P. sold 12,086 shares and Bessemer Venture Partners X Institutional L.P. sold 11,346 shares at a weighted average price of $40.096, in multiple trades between $40.025 and $40.115. On February 13, 2026, BVP X sold 77,328 shares and BVP X Inst sold 72,591 shares at a weighted average price of $40.109, with prices ranging from $39.50 to $40.722. Elliott has an indirect, passive economic interest in these Bessemer funds and disclaims beneficial ownership of their securities except to the extent of his pecuniary interest.
Hinge Health, Inc. received an amended Schedule 13G showing that Daniel Antonio Perez beneficially owns 10,373,350 shares of Class A common stock on an as-converted basis, representing 15.7% of the class.
This percentage is based on 55,883,690 Class A shares outstanding as of December 31, 2025. The position includes 9,822,175 Class A shares underlying Class B shares held by Perez, 515,705 Class A shares underlying Class B shares held by his spouse, and 35,470 Class A shares held directly by his spouse. Perez has sole voting and dispositive power over 9,822,175 shares and shared power over 551,175 shares.
Alkeon Capital Management LLC and Panayotis D. Sparaggis have filed an amended Schedule 13G reporting beneficial ownership in Hinge Health, Inc. Class A common stock. They report holding 791,104 shares, representing 2.1% of the Class A shares outstanding.
The ownership percentages are based on 37,919,155 Class A shares outstanding as of October 30, 2025, as disclosed in Hinge Health’s Form 10-Q for the quarter ended September 30, 2025. Both reporting persons list shared voting and dispositive power over the same 791,104 shares and no sole power.
The filing date of the signatures is February 13, 2026, with an event date triggering the filing of December 31, 2025. The filing confirms that the reporting persons’ holdings are 5 percent or less of Hinge Health’s Class A common stock.